Categories: DNANews

LICORbio Expands Portfolio with Strategic Acquisition of SERVA Electrophoresis

LINCOLN, Neb. and HEIDELBERG, Germany, July 1, 2025 /PRNewswire/ — LICORbio, a leading innovator in life science imaging and analytical solutions, today announced the acquisition of SERVA Electrophoresis, a privately held company known for its high-quality electrophoresis reagents, consumables, and workflow instrumentation. The transaction strengthens LICORbio’s position as a comprehensive solutions provider in protein analysis and enhances its commitment to driving innovation in life sciences research.

The acquisition significantly broadens LICORbio’s electrophoresis offerings, allowing the company to deliver an end-to-end workflow with an expanded suite of products tailored to the evolving needs of proteomics researchers worldwide. The integration of SERVA’s proprietary technologies with LICORbio’s industry-leading imaging platforms will provide customers with complete workflow solutions from sample preparation to resolution, to imaging and best in class quantification.

“This acquisition reflects LICORbio’s strategic focus on expanding our core technologies while staying close to the needs of the research community,” said Tom Reslewic, chief executive officer of LICORbio. “By integrating SERVA’s expansive electrophoresis products with our established imaging platforms, we’re enabling more accurate, reproducible, and efficient protein, DNA, and RNA analysis workflows.”

“We’re thrilled to welcome the SERVA team into LICORbio,” said Bambi Reynolds, senior vice president and general manager of LICORbio. “This is more than a product expansion, it’s an opportunity to bring integrated solutions and talented people together who share a commitment to supporting the scientific community. Our teams are energized by the possibilities this integration brings, and we’re excited to build a unified strategy centered on innovation, collaboration and customer outcomes.”

Founded in 1953, SERVA has built a reputation for innovation in gel electrophoresis, offering an expansive catalog of reagents and consumables with robust performance across a wide range of applications. Their technology complements LICORbio’s existing portfolio and aligns with its mission to empower discovery through accessible, high-quality tools.

The acquisition is effective immediately, with integration activities already underway. As part of the acquisition, LICORbio will maintain SERVA’s Heidelberg location, honoring its legacy while scaling support through LICORbio’s global infrastructure. Customers can expect uninterrupted access to SERVA’s full product line, with enhanced service and support and integrated imaging solutions.

About LICORbio
LICORbio is a leading developer of imaging systems and analytical tools that empower scientists to uncover new insights in proteomics, genomics, and cell biology. With a heritage of innovation and a commitment to research excellence, LICORbio delivers trusted solutions that accelerate discovery and reproducibility in the lab.

For more information, visit LICORbio.com.

Media Contact:
Katie Schaepe
Director of Marketing
LICORbio
katie.schaepe@licorbio.com
402-467-0800

View original content to download multimedia:https://www.prnewswire.com/news-releases/licorbio-expands-portfolio-with-strategic-acquisition-of-serva-electrophoresis-302495981.html

SOURCE LICORbio

Staff

Recent Posts

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…

9 hours ago

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…

12 hours ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…

12 hours ago

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

12 hours ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…

12 hours ago